RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+55.06%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.8B
AUM Growth
+$2.8B
(+33%)
Cap. Flow
+$38.5M
Cap. Flow
% of AUM
1.38%
Top 10 Holdings %
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
26
Closed
5
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$67.7M |
| 2 |
Immunome
IMNM
|
$41.5M |
| 3 |
Biohaven
BHVN
|
$39.6M |
| 4 |
ALX Oncology
ALXO
|
$35.4M |
| 5 |
IDEAYA Biosciences
IDYA
|
$33.3M |
Top Sells
| 1 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$100M |
| 2 |
Krystal Biotech
KRYS
|
$33.5M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$32M |
| 4 |
Amicus Therapeutics
FOLD
|
$30M |
| 5 |
Elevance Health
ELV
|
$29.4M |
Sector Composition
| 1 | Healthcare | 94.12% |
| 2 | Industrials | 3.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $487M | 17.42% | 16,423,922 -1,079,495 | -6% | -$32M |
|
|
2
Krystal Biotech
KRYS
$4.27B
| $215M | 7.69% | 1,733,189 -270,178 | -13% | -$33.5M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $210M | 7.53% | 14,828,321 -2,116,300 | -12% | -$30M |
|
4
Scholar Rock
SRRK
$3.14B
| $120M | 4.31% | 6,402,505 +1,669,257 | +35% | +$31.4M |
|
|
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $115M | 4.13% | 1,857,706 | – | – |
|
|
AUGX
6
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $95.8M | 3.43% | 16,380,327 +750,000 | +5% | +$4.39M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $77.4M | 2.77% | 4,801,540 +326,156 | +7% | +$5.26M |
|
|
8
SPDR S&P 500 ETF Trust
SPY
$658B
| $67.7M | 2.42% | +142,500 | New | +$67.7M |
|
9
Regenxbio
RGNX
$451M
| $67.5M | 2.41% | 3,760,690 +1,186,648 | +46% | +$21.3M |
|
|
10
Biohaven
BHVN
$1.63B
| $61.8M | 2.21% | 1,444,365 +925,441 | +178% | +$39.6M |
|
11
Zymeworks
ZYME
$1.12B
| $60.2M | 2.15% | 5,790,230 +129,000 | +2% | +$1.34M |
|
12
LivaNova
LIVN
$3.08B
| $58.8M | 2.1% | 1,137,068 +36,576 | +3% | +$1.89M |
|
|
13
ALX Oncology
ALXO
$62.7M
| $54.5M | 1.95% | 3,659,264 +2,375,975 | +185% | +$35.4M |
|
|
CTLT
14
DELISTED
CATALENT, INC.
CTLT
| $49.4M | 1.77% | 1,100,466 +226,500 | +26% | +$10.2M |
|
15
Fate Therapeutics
FATE
$120M
| $49.3M | 1.76% | 13,169,057 +44,630 | +0.3% | +$167K |
|
16
Pliant Therapeutics
PLRX
$101M
| $48.8M | 1.75% | 2,696,648 +18,549 | +0.7% | +$336K |
|
17
Kymera Therapeutics
KYMR
$2.95B
| $46.4M | 1.66% | 1,823,956 -44,551 | -2% | -$1.13M |
|
|
18
Immunome
IMNM
$828M
| $41.5M | 1.48% | +3,879,415 | New | +$41.5M |
|
19
Immunovant
IMVT
$2.56B
| $41.2M | 1.47% | 977,072 -125,442 | -11% | -$5.28M |
|
20
Boston Scientific
BSX
$156B
| $40.1M | 1.43% | 693,200 -81,000 | -10% | -$4.68M |
|
21
Shattuck Labs
STTK
$47M
| $40.1M | 1.43% | 5,619,914 | – | – |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $39.4M | 1.41% | 993,803 -642,135 | -39% | -$25.5M |
|
23
Beam Therapeutics
BEAM
$1.66B
| $38.9M | 1.39% | 1,429,783 -39,942 | -3% | -$1.09M |
|
24
Absci
ABSI
$357M
| $33.7M | 1.21% | 8,031,094 | – | – |
|
25
Nurix Therapeutics
NRIX
$714M
| $33.6M | 1.2% | 3,256,519 +407,692 | +14% | +$4.21M |
|